Dulac Edward J III's Form 4 filing
Fate Therapeutics Inc (FATE) · filed Aug 19, 2022
- Accession no.
- 0001209191-22-046929
- Filed
- Aug 19, 2022
- Trade date
- Aug 18, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $153.1K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dulac Edward J IIICIK 0001821530 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2022 | Common Stock | SSaleDisposed | −4,703 | $29.75 | −$139,914.25 | 137,233 | Direct | |
| Aug 18, 2022 | Common Stock | SSaleDisposed | −432 | $30.41 | −$13,137.12 | 136,801 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.